Risk of Arterial and Venous Thromboembolic Events with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor A (VEGF-A): A Systematic Review and Meta-Analysis

Risk of Arterial and Venous Thromboembolic Events with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor A (VEGF-A): A Systematic Review and Meta-Analysis

Mihika Shah

Contact

Mandar Kalpesh Shah

Contact

Sharan Dharmesh Shah

Contact

Harshil Devang Patel

Contact

Dr. Mamta Gupta

Contact

Risk of Arterial and Venous Thromboembolic Events with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor A (VEGF-A): A Systematic Review and Meta-Analysis

Article Fingerprint

ReserarchID

PDDTM84L1I

AI TAKEAWAY

Connecting with the Eternal Ground

Abstract

Bevacizumab, a humanized antibody against VEGF, is effective within the treatment of patients with several cancers. However, like several therapeutic agents, important side effects such as arterial thromboembolism, venous thromboembolism, hypertension, neutropenia, proteinuria, and hemorrhage are related to bevacizumab. Thromboembolism is one of the leading causes of morbidity and mortality in patients with cancer. Considerations have arisen relating to the chance of venous and arterial thromboembolism with the novel antiangiogenic agent bevacizumab: a recombinant humanized monoclonal antibody to a vascular endothelial growth factor which is wide employed in cancer treatment.

References

25 Cites in Article

Reference Format

N Ferrara (2004). Vascular endothelial growth factor: basic science and clinical progress.
J Ebos,C Lee,R Kerbel (2009). Tumor and hostmediated pathways of resistance and disease progression in response to antiangiogenic therapy.
N Tebbutt,F Murphy,D Zannino,K Wilson,M Cummins,E Abdi,A Strickland,R Lowenthal,G Marx,C Karapetis,J Shannon,D Goldstein,S Nayagam,R Blum,L Chantrill,R Simes,T Price (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
S Nalluri,D Chu,R Keresztes,X Zhu,S Wu (2008). Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a metaanalysis.
Elaine Beller,Paul Glasziou,Douglas Altman,Sally Hopewell,Hilda Bastian,Iain Chalmers,Peter Gøtzsche,Toby Lasserson,David Tovey (2013). PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts.
Atsushi Ohtsu,Manish Shah,Eric Van Cutsem,Sun Rha,Akira Sawaki,Sook Park,Ho Lim,Yasuhide Yamada,Jian Wu,Bernd Langer,Michal Starnawski,Yoon-Koo Kang (2011). Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study.
Bernard Escudier,Anna Pluzanska,Piotr Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,Marek Filipek,Bohuslav Melichar,Emilio Bajetta,Vera Gorbunova,Jacques-Olivier Bay,Istvan Bodrogi,Agnieszka Jagiello-Gruszfeld,Nicola Moore (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
C Aghajanian,S Blank,B Goff,P Judson,M Teneriello,A Husain,M Sovak,J Yi,L Nycum (2012). OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
David Miles,Arlene Chan,Luc Dirix,Javier Cortés,Xavier Pivot,Piotr Tomczak,Thierry Delozier,Joo Sohn,Louise Provencher,Fabio Puglisi,Nadia Harbeck,Guenther Steger,Andreas Schneeweiss,Andrew Wardley,Andreas Chlistalla,Gilles Romieu (2010). Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer.
Eric Van Cutsem,Walter Vervenne,Jaafar Bennouna,Yves Humblet,Sharlene Gill,Jean-Luc Van Laethem,Chris Verslype,Werner Scheithauer,Aijing Shang,Jan Cosaert,Malcolm Moore (2009). Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer.
F Kabbinavar,J Schulz,M Mccleod,T Patel,J Hamm,J Hecht,R Mass,B Perrou,B Nelson,W Novotny (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John Hainsworth,William Heim,Jordan Berlin,Ari Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert Ross,Fairooz Kabbinavar (2004). Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer.
H Hurwitz,L Fehrenbacher,J Hainsworth,W Heim,J Berlin,E Holmgren,J Hambleton,W Novotny,F Kabbinavar (2005). Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Herbert Hurwitz,Niall Tebbutt,Fairooz Kabbinavar,Bruce Giantonio,Zhong-Zhen Guan,Lada Mitchell,Daniel Waterkamp,Josep Tabernero (2013). Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials.
M Reck,Von Pawel,J Zatloukal,P Ramlau,R Gorbounova,V Hirsh,V Leighl,N Mezger,J Archer,V Moore,N Manegold,C (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL.
Nicholas Robert,Véronique Diéras,John Glaspy,Adam Brufsky,Igor Bondarenko,Oleg Lipatov,Edith Perez,Denise Yardley,Stephen Chan,Xian Zhou,See-Chun Phan,Joyce O'shaughnessy (2011). RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer.
Robert Burger,Mark Brady,Michael Bookman,Gini Fleming,Bradley Monk,Helen Huang,Robert Mannel,Howard Homesley,Jeffrey Fowler,Benjamin Greer,Matthew Boente,Michael Birrer,Sharon Liang (2011). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer.
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Xiaoqing Liu,Yunzhong Zhu,Shun Lu,Jifeng Feng,Jianxing He,Baohui Han,Jie Wang,Guoliang Jiang,Chunhong Hu,Hao Zhang,Gang Cheng,Xiangqun Song,You Lu,Hongming Pan,Wenjuan Zheng,Anny-Yue Yin (2015). BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer.
Hedy Kindler,Donna Niedzwiecki,Donna Hollis,Susan Sutherland,Deborah Schrag,Herbert Hurwitz,Federico Innocenti,Mary Mulcahy,Eileen O'reilly,Timothy Wozniak,Joel Picus,Pankaj Bhargava,Robert Mayer,Richard Schilsky,Richard Goldberg (2010). Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303).
H Kindler,T Karrison,D Gandara,C Lu,L Krug,J Stevenson,P Jänne,D Quinn,M Koczywas,J Brahmer,K Albain (2012). Multicenter, doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Saadettin Kilickap,Hüseyin Abali,Ismail Celik (2003). Bevacizumab, Bleeding, Thrombosis, and Warfarin.
Ian Zachary (2001). Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.
B Tam,K Wei,J Rudge,J Hoffman,J Holash,S Park,J Yuan,C Hefner,C Chartier,J Lee,S Jiang (2006). VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.
B Hesser,X Liang,G Camenisch,S Yang,D Lewin,R Scheller,N Ferrara,H Gerber (2004). Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells.
B Kuenen,M Levi,J Meijers,A Kakkar,V Van Hinsbergh,P Kostense,H Pinedo,K Hoekman (2002). Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Mihika Shah. 2020. \u201cRisk of Arterial and Venous Thromboembolic Events with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor A (VEGF-A): A Systematic Review and Meta-Analysis\u201d. Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 20 (GJMR Volume 20 Issue B1): .

More Citation Formats

Select Citation Style:

Download Citation

Download Article

GJMR Volume 20 Issue B1
Pg. 71- 85

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-B Classification: NLMC Code: WG 610

Submission ReceivedDecember 11, 2019
Peer Review Double Blind
Handling Editor
Accepted January 3, 2020
Published January 15, 2020

Version of record

v1.2

Issue date

February 22, 2020

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 2466

Total Downloads: 1360

2026 Trends

Published Article

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]